New drug cocktail aims to slow kidney disease in IgA patients
NCT ID NCT07030894
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests whether combining budesonide (Nefecon) and ambrisentan can reduce protein in the urine and preserve kidney function in people with IgA nephropathy who are at risk of kidney failure. About 129 adults will take both pills daily for 36 weeks. Researchers will measure changes in urine protein, kidney filtration rate, and immune markers to see if the combination is safe and effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
budesonide (Nefecon) and ambrisentan
What this could lead to
If successful, this combination could offer a new way to slow kidney damage and delay the need for dialysis or transplant in people with IgA nephropathy.
What could go wrong
This is a single-arm, early-phase trial with no placebo group, so results may be less reliable. Side effects from the drugs are possible, and the benefit may not be confirmed in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Hospital of Jilin University
RECRUITINGChangchun, Jilin, 130021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••